Glioblastoma Multiforme with Subcutaneous Metastases, Case Report and Literature Review

Liemei Guo, M.D., Yongming Qiu, M.D., Ph.D., Jianwei Ge, M.D., Dongxue Zhou, M.D.
Department of Neurosurgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Gamma-knife treatment Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Glioblastoma multiforme (GBM) is the most common primary brain tumor and the most malignant astrocytoma in adults, with rare extra-cranial metastases, especially for subcutaneous metastases. It could be easily misdiagnosed as primary subcutaneous tumor. In this report, we describe a patient with pontine GBM who developed a subcutaneous swelling at the ipsilateral posterior cervical region 8 months after operation, and the pathological and immunocytochemical examination carry the same characteristics as the primary intracranial GBM cells, which defined it as subcutaneous metastasis. GBM with subcutaneous metastasis is extremely rare, and knowledge of a prior intracranial GBM, pathological examinations and immunocytochemical tests with markers typically expressed by GBM are of vital importance for the diagnosis of GBM metastasis. Surgical resection of subcutaneous swelling, followed by chemotherapy and radiotherapy, could be the best strategy of treatment for the patients with GBM subcutaneous metastasis.

**Key Words:** Glioblastoma multiforme · Glioblastoma metastasis · Subcutaneous metastasis · Extracranial metastasis.

**INTRODUCTION**

Glioblastoma multiforme (GBM) with subcutaneous metastases is extremely rare, and most proceeded after an invasive intracranial procedure (craniotomy or biopsy). Here, we present 1 patient with pontine GBM metastasizing to subcutaneous tissue of the ipsilateral posterior cervical region. Furthermore, reasons for rarity, mechanisms, the diagnosis, and treatments of GBM with extracranial metastasis were reviewed.

**CASE REPORT**

A 19-year-old female patient presented with debility of left limbs for 2 days. Neurological examination revealed muscle strength of left limbs was graded IV. Cranial magnetic resonance (MR) showed a cystic mass measuring 2.0×2.5×3.0 cm located at the right part of pons; contrast MR (Fig. 1) showed the tumor was ring-enhanced with necrosis. The operation was performed via retro-sigmoid approach, and pathological examinations of the lesion confirmed as GBM (World Health Organization grade IV) that had variable histological features, such as mitosis, endothelial proliferation and necrosis (Fig. 2A-D). Immunohistochemical results showed that the tumor cells were positive for glial fibrillary acidic protein (GFAP) and S-100 protein (Fig. 2E, F). After operation, the patient was treated with three-dimensional conformal radiotherapy for 6 weeks (60 Gy in total with 30 fractions of 2 Gy) and concomitant temozolomide chemotherapy (75 mg/m²/daily for 42 d). After that, adjuvant temozolomide chemotherapy (150 mg/m²/daily for 5 d with every 28 d for 1 chemotherapy course) was suggested; however, the patient’s family refused that because of financial reasons. 8 months after operation, the patient noticed an enlarging subcutaneous swelling at the left posterior cervical region. On examination, a very firm, immobile subcutaneous swelling measured 2.5×3.0 cm was palpated. Follow-up MR (Fig. 3) scan showed that recurrence of pontine GBM, and an enhanced subcutaneous swelling at the left posterior cervical region was evident on magnetic resonance imaging. The swelling was resected, and pathological examinations, immunohistochemical results showed the same characteristics as the primary intracranial
GBM cells (Fig. 4). Thus, a diagnosis of GBM metastasizing to the cervical subcutaneous tissue was rendered. As a result, temozolomide chemotherapy (150 mg/m²/daily for 5 d) and radiotherapy was administrated to the patient. 6-month-long follow up showed that there was no recurrence of the cervical subcutaneous tumor.

**DISCUSSION**

We feel that reporting of this rare case is of great significance for two reasons:

1) GBM with subcutaneous metastasis is extremely rare, and it is often misdiagnosed as primary subcutaneous tumor, which could delay effective treatments; and

2) Knowledge of a prior intracranial GBM, pathological examinations and immunocytochemical tests with markers typically expressed by GBM are critical for accurate diagnosis.

Although being exceedingly aggressive, GBM extremely rarely metastasize to the subcutaneous tissue. Including of our case described previously, only 10 cases with GBM subcutaneous metastases have been reported (Table 1).

Some scholars ascribed the rarity of GBM extracranial metastasis to the short survival of the disease. Other scholars suggested that GBM are prevented from metastasizing because of lack of true lymphatics in the brain, the relatively impassable dura, extracellular matrix, and tough basement membrane surrounding intracerebral blood vessels. However, craniotomy breaches the brain’s innate defensive systems, enabling tumor cells to gain entry to the lymphatic system, meningeal and vertebral venous system at the dural or intracerebral level. It was reported that most of the GBM metastases occurred after craniotomy or stereotactic biopsies or intraventricular shunts.

In the present case, we supposed the subcutaneous swelling could be spread through local dissemination since the swelling was just located 3 cm below the original suture line. However, ho-
mogenous metastasis, possibly through venous system could not be eliminated, as the swelling acquired a close relationship with the external jugular vein. In addition, it could not be excluded that the subcutaneous metastasis was spread through cerebrospinal fluid (CSF) dissemination, as the retrosigmoid approach is notoriously prone to leaking, and the CSF easily leak into the subcutaneous space, through the retrosigmoid opening into the sternocleidomastoid, and rectus capitus lateralis muscles. Overall, it may be difficult or impossible to distinguish that the true metastatic swelling was spread by local dissemination or CSF dissemination or hematogenous metastasis after operation in the case of lesions of subcutaneous tissue in close proximity to the craniotomy site.

As GBM with subcutaneous metastasis is rare, a clinical history of a pre-exist-

Table 1. Summary of reports in the literature and the present case on subcutaneous metastasis from intracranial GBM

<table>
<thead>
<tr>
<th>References</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Primary site</th>
<th>Metastatic site</th>
<th>Treatments after operation/biopsy</th>
<th>Time interval from operation/biopsy to metastasis</th>
<th>Intracranial recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figueroa et al.</td>
<td>M</td>
<td>35</td>
<td>Temporal lobe</td>
<td>3.5 cm firm anterior scalp mass 2 cm posterior to the frontal scalp line</td>
<td>Radiotherapy for 3 months</td>
<td>8 months</td>
<td>Yes</td>
</tr>
<tr>
<td>Santos et al.</td>
<td>M</td>
<td>42</td>
<td>Supra-tentorial area</td>
<td>Skin and subcutaneous tumor seeding</td>
<td>Not in detail</td>
<td>3 years</td>
<td>No</td>
</tr>
<tr>
<td>Allan et al.</td>
<td>M</td>
<td>60</td>
<td>Frontal-temporal lobe</td>
<td>Subcutaneous nodules in the scalp of craniotomy</td>
<td>Radiotherapy</td>
<td>1 year</td>
<td>Yes</td>
</tr>
<tr>
<td>Bouillot-Eimer et al.</td>
<td>F</td>
<td>60</td>
<td>Parietal lobe</td>
<td>Subcutaneous tumor in the left occipital region</td>
<td>Radiotherapy and chemotherapy, only biopsy without tumor resection</td>
<td>8 months</td>
<td>Yes</td>
</tr>
<tr>
<td>Jain et al.</td>
<td>M</td>
<td>49</td>
<td>Temporal-parietal lobe</td>
<td>Adjacent to the scar</td>
<td>Radiotherapy</td>
<td>10 months</td>
<td>Yes</td>
</tr>
<tr>
<td>Saad et al.</td>
<td>M</td>
<td>13.5</td>
<td>Frontal lobe</td>
<td>Cranial skin and soft tissue through skull defect; spine leptomeninges</td>
<td>Adjuvant temozolomide chemotherapy and radiotherapy for 4 weeks</td>
<td>9 months</td>
<td>Yes</td>
</tr>
<tr>
<td>Mentrikoski et al.</td>
<td>F</td>
<td>58</td>
<td>Frontal lobe</td>
<td>Adjacent to the craniotomy site</td>
<td>Adjuvant chemotherapy and radiotherapy</td>
<td>16 months after the first operation and 11 months after the second operation</td>
<td>Yes</td>
</tr>
<tr>
<td>Miliaras et al.</td>
<td>M</td>
<td>41</td>
<td>Not in detail</td>
<td>Close to the original craniotomy suture line</td>
<td>Radiotherapy</td>
<td>2 months</td>
<td>Not in detail</td>
</tr>
<tr>
<td>Miliaras et al.</td>
<td>M</td>
<td>63</td>
<td>Fronto-parietal lobe</td>
<td>Scapular subcutaneous mass</td>
<td>Not in detail</td>
<td>7 months</td>
<td>Yes, with multifocal lesion</td>
</tr>
<tr>
<td>Present case</td>
<td>F</td>
<td>19</td>
<td>Pons of Brain stem</td>
<td>Ipsilateral posterior cervical region</td>
<td>Adjuvant chemotherapy and radiotherapy</td>
<td>8 months</td>
<td>Yes</td>
</tr>
</tbody>
</table>

GBM: glioblastoma multiforme, M: male, F: female

Fig. 4. Pathological and Immunohistochemical examinations of the subcutaneous swelling. A (HE×50) shows a low-power view features of the tumor cell; B-C (HE×200), D (HE×400) shows variable histological features, such as endothelial proliferation, necrosis and mitosis. When compared with the primary pathological examinations, mitosis and tumor necrosis were more frequent. Immunohistochemical results revealed that the tumor cells were strongly positive for glial fibrillary acidic protein (E×200) and S-100 protein (F×200), which showed the same characteristics as the primary intracranial glioblastoma multiforme cells.
ing glioma is critical for accurate diagnosis. Knowledge of a prior intracranial GBM lead us to evaluate the tumor with immunocytochemical markers typically expressed by GBM, such as GFAP, S-100, helping to confirm the diagnosis. GEAP-positivity indicated it could originate from intracranial astrocyte, which is of great importance for the diagnosis of metastatic intracranial glioma. Therefore, pathological and immunocytochemical examinations of the tumor after surgical resection or biopsy are of vital importance for the diagnosis of GBM metastasis. However, in the case of extracranial subcutaneous metastasis, a differential diagnosis with other small cell carcinoma, poorly differentiated carcinoma and neuroblastoma should also be considered.

The standard therapy for GBM consists of surgical resection to the extent that is feasible safely, followed by radiotherapy plus concomitant and adjuvant temozolomide chemotherapy. the soft-tissue metastases, surgical resection or biopsy is recommended to confirm the extracranial metastasis, followed by chemotherapy and radiotherapy. Steinbok et al. reported that cervical tumor decreased in size, indicating sensitivity to lomustine, but intracranial tumor was not responded. Possible explanations of this phenomenon are inadequate drug delivery to the intracranial tumor, different sensitivity of intracranial and extracranial tumors to the drug, or a combination of these factors. In the present case, after resecting the subcutaneous swelling, temozolomide chemotherapy and radiotherapy was administered to the patient immediately, and 6-month-long follow-up showed that the outcome was good without recurrence of the subcutaneous tumor. We suggest that surgical resection of GBM subcutaneous metastasis to the extent, followed by chemotherapy and radiotherapy, could be the best strategy of treatments for the patients.

**CONCLUSION**

In summary, GBM with subcutaneous extracranial metastasis is extremely rare. Knowledge of a prior intracranial GBM, pathological and immunocytochemical examinations with markers typically expressed by GBM are vital important for the diagnosis of GBM metastasis. Surgical resection of subcutaneous swelling, followed by chemotherapy and radiotherapy, could be the best strategy of treatment for the patients with GBM subcutaneous metastasis.

**References**

1. Allan RS: Scalp metastasis from glioblastoma. J Neurol Neurosurg Psychiatry 75 : 559, 2004